Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.

Amagai, Yosuke

Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. [electronic resource] - Japanese journal of clinical oncology Jun 2010 - 503-7 p. digital

Publication Type: Journal Article

1465-3621

10.1093/jjco/hyp200 doi


Animals
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Benzenesulfonates--administration & dosage
Carcinoma, Renal Cell--drug therapy
Cell Line, Tumor
Female
Interleukin-2--administration & dosage
Kidney Neoplasms--drug therapy
Lung Neoplasms--mortality
Mice
Mice, Inbred BALB C
Nephrectomy
Niacinamide--analogs & derivatives
Phenylurea Compounds
Pyridines--administration & dosage
Recombinant Proteins--administration & dosage
Sorafenib
Survival Rate